Platelet transfusion to prevent or treat bleeding due to thrombocytopenia is standard therapy worldwide.
1 In recent years, the risk of transfusion-transmitted infections (TTIs) has been greatly reduced.
2 However, infectious agent transmission—in particular, bacteria—remains a significant risk associated with platelet transfusion.
3-5 One solution to further reduce the risk of TTIs is photochemical pathogen reduction (PR),
6 a process by which pathogens are significantly depleted in number,
7 albeit with some exceptions.
8,9 However, PR technologies, such as amotosalen–UV-A treatment, induce functional platelet alterations.
10,11 Previous clinical studies
12,13 have raised concerns about the clinical effectiveness of pathogen-reduced platelets compared with standard untreated platelets. A 2013 Cochrane meta-analysis
14 of published clinical trials reported a nonstatistically significant relative risk of 1.06 (95% CI, 0.93-1.21;
P = .39) with regard to grade 2 or higher bleeding associated with pathogen-reduced platelets and concluded that not enough evidence was available to be sure that such platelets work as effectively as standard platelets to prevent bleeding. A recently updated analysis
15 reported a 1.10 (95% CI, 0.97-1.25;
P = .15) relative risk of grade 2 or higher bleeding associated with pathogen-reduced platelets.